DOCSLIB.ORG

Metronidazole, Topical 385

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

PART13.MIF Page 385 Friday, October 31, 2003 11:10 AM Metronidazole, topical 385 Methoxsalen. Dermatologic indications and dosage Disease Adult dose Child dose Component of Systemic photochemotherapy – Systemic photochemotherapy – photochemotherapy 0.4–0.6 mg per kg PO 1.5 hours 0.4–0.6 mg per kg PO 1.5 hours – psoriasis; Reiter before exposure to ultraviolet A before exposure to ultraviolet A syndrome; cutaneous light, either via light box, outdoor light, either via light box, outdoor T cell lymphoma sunlight, or photopheresis; topical sunlight, or photopheresis; topical (mycosis fungoides; therapy – 0.1% lotion applied therapy – 0.1% lotion applied Sézary syndrome; 30 minutes before exposure to 30 minutes before exposure to vitiligo; ultraviolet A light ultraviolet A light polymorphous light eruption; solar urticaria; chronic actinic dermatitis; morphea; linear scleroderma; graft versus host disease; lymphomatoid papulosis Component of 0.4–0.6 mg per kg PO 1.5 hours 0.4–0.6 mg per kg PO 1.5 hours photopheresis – T-cell before exposure to ultraviolet A before exposure to ultraviolet A lymphoma (mycosis light light fungoides; Sézary syndrome) M Contraindications/precautions Drug class Hypersensitivity to drug class or compo- Nitroimidazole antibiotic nent Mechanism of action References DNA disruption and inhibition of nucleic Laube S, George SA (2001) Adverse effects with acid synthesis (may not be mechanism in PUVA and UVB phototherapy. Journal of Der- skin disease treatment) matological Treatment 12(2):101–105 Lim HW, Edelson RL (1995) Photopheresis for the Dosage form treatment of cutaneous T-cell lymphoma. He- matology – Oncology Clinics of North America 0.75% cream, gel; 1% cream 9(5):1117–1126 Dermatologic indications and dosage See table Metronidazole, topical Common side effects Cutaneous: burning sensation, erythema, skin eruption Trade name(s) MetroGel; MetroCream; MetroLotion; Nori- Serious side effects tate None Generic available Drug interactions Ye s None PART13.MIF Page 386 Friday, October 31, 2003 11:10 AM 386 Michelin tire baby syndrome Metronidazole, topical. Dermatologic indications and dosage Disease Adult dosage Child dosage Rosacea Apply once daily Apply once daily Contraindications/precautions smooth muscle hamartoma. Pediatric Derma- Hypersensitivity to drug class or compo- tology 6(4):329–331 nent References Cohen AF, Tiemstra JD (2002) Diagnosis and treatment of rosacea. Journal of the American Michelin tire syndrome Board of Family Practice 15(3):214–217 Michelin tire baby syndrome Michelin tire baby syndrome Miescher syndrome 2 Synonym(s) Michelin tire syndrome; Kunze Riehm syn- drome Berardinelli-Seip syndrome Definition Heterogeneous group of disorders charac- terized by ringed creases of the extremities Miescher-Melkersson- Pathogenesis Rosenthal syndrome Autosomal dominant trait; at least two dis- tinct chromosomal abnormalities Cheilitis granulomatosa Clinical manifestation Deep, gyrus-like skin folds on the back; cir- cumferential, deep skin folds of limbs, with spontaneous resolution of skin creases in childhood; loose, thick skin; xanthomas Miescher’s cheilitis and/or lipomas; hypertrichosis with under- granulomatosa lying smooth muscle hamartoma; cleft pal- ate; neuroblastoma; congenital heart defects Cheilitis granulomatosa Differential diagnosis Nevus lipomatosis Therapy None Miescher’s granulomatosis References Glover MT, Malone M, Atherton DJ (1989) Miche- Actinic granuloma lin-tire baby syndrome resulting from diffuse Cheilitis granulomatosa PART13.MIF Page 387 Friday, October 31, 2003 11:10 AM Miliaria 387 rity of the sweat ducts in neonates, lack of Migratory necrolytic acclimitization, occlusive clothing, hot and erythema humid conditions, vigorous exerciose, and bacterial overgrowth Definition Clinical manifestation Miliaria crystallina: usually affects neonates Migratory eruption on face, abdomen, peri- neum, buttocks, or lower extremities, usu- and adults who are febrile or who recently ally associated with underlying glucagon- moved to a tropical climate; asymptomatic, oma clear, superficial vesicles appear in crops, often confluent, and without surrounding Glucogonoma erythema; rupture easily and resolve with superficial, branny desquamation; occur References within days to weeks of exposure to hot Schwartz RA (1997) Glucagonoma and pseudog- weather and disappear within hours to lucagonoma syndromes. International Journal days; in infants, lesions occur on the head, of Dermatology 36(2):81–89 neck, and upper part of the trunk; in adults, lesions appear on the trunk Miliaria rubra: occurs in hot, humid envi- ronments; pruritic or painful, small, dis- Mikulicz disease crete, non-follicular, erythematous papules and vesicles; lesions on the neck and in the groin and axillae; lesions on covered skin Rhinoscleroma subject to friction, such as the neck, scalp, upper part of the trunk, and flexures in M adults Miliaria profunda: occurs in those in a trop- Miliaria ical climate who have had repeated epi- sodes of miliaria rubra; asymptomatic, firm, flesh-colored papules, usually on the Synonym(s) trunk, developing within minutes or hours Prickly heat; sudamina; heat rash; lichen after the stimulation of sweating and tropicus; tropical anhidrosis resolves quickly after removal of stimulus that caused sweating; increased sweating in Definition unaffected skin; lymphadenopathy; hyper- Disorder of the eccrine sweat glands often pyrexia and symptoms of heat exhaustion, occurring in conditions of increased heat including dizziness, nausea, dyspnea, and and humidity, caused by blockage of the palpitations sweat ducts that results in the leakage of eccrine sweat into skin Differential diagnosis Folliculitis; milia; viral exanthem; cutane- Pathogenesis ous candidiasis; erythema toxicum; insect Occlusion of the skin, due to clothing or bite reaction; scabies; foreign body reac- bandages, resulting in pooling of sweat on tion; drug eruption; cholinergic urticaria the skin surface and overhydration of the stratum corneum; in susceptible persons, Therapy including infants, with relatively immature Miliaria crystallina: no therapy indicated eccrine glands, stratum corneum overhy- Miliaria rubra: removal of occlusive cloth- dration causes transient blockage of the ing; limiting of activity; air conditioning acrosyringium, resulting in leakage of Miliaria profunda: removal of occlusive sweat; other contributing factors: immatu- clothing; limited activity; air conditioning; PART13.MIF Page 388 Friday, October 31, 2003 11:10 AM 388 Miliaria cystallina anhydrous lanolin lotion applied 2–3 times secondary milia result from damage to daily and before activity that may produce pilosebaceous unit after skin trauma excess sweating Clinical manifestation References Uniform, pearly-white to yellowish, small, Wenzel FG, Horn TD (1998) Nonneoplastic disor- domed papules, often in groups; primary ders of the eccrine glands. Journal of the Amer- milia: usually on the face of newborns; seen ican Academy of Dermatology 38(1):1–17 around the eye in children and adults; sec- ondary lesions: arise after blistering or trauma, including bullous pemphigoid, inherited and acquired epidermolysis bul- Miliaria cystallina losa, bullous lichen planus, porphyria cuta- nea tarda, and burns Miliaria Differential diagnosis Acne vulgaris; flat wart; syringoma; trich- oepithelioma; xanthoma Miliaria profunda Therapy Incision and drainage; light hyfrecation Miliaria References Touart DM, Sau P (1998) Cutaneous deposition diseases. Part I. Journal of the American Acad- Miliaria pustulosa emy of Dermatology. 39(2 Pt 1):149–171 Miliaria Minocycline Miliary tuberculosis of the Trade name(s) skin Minocin; Dynacin; Vectrin Generic available Cutaneous tuberculosis Ye s Drug class Tetracycline Milium Mechanism of action Antibiotic activity: protein synthesis inhibi- Synonym(s) tion by binding to the 30S ribosomal subu- None nit; anti-inflammatory activity: unclear mechanism Definition Small, benign, keratin-filled cyst Dosage form 50 mg, 75 mg, 100 mg tablets Pathogenesis Derived from the pilosebaceous follicle; pri- Dermatologic indications and dosage mary lesions arise from vellus hair follicles; See table PART13.MIF Page 389 Friday, October 31, 2003 11:10 AM Minocycline 389 Minocycline. Dermatologic indications and dosage Disease Adult dosage Child dosage Acne vulgaris 50–100 mg PO twice daily > 8 years old – 50–100 mg PO twice daily Atrophoderma of 50–100 mg PO twice daily > 8 years old – 50–100 mg PO twice Pasini-Pierini daily Bullous pemphigoid 50–100 mg PO twice daily > 8 years old – 50–100 mg PO twice daily Confluent and 50–100 mg PO twice daily > 8 years old – 50–100 mg PO twice reticulate daily papillomatosis of Gougerot and Carteaud Dermatitis 50–100 mg PO twice daily > 8 years old – 50–100 mg PO twice herpetiformis daily Folliculitis 50–100 mg PO twice daily > 8 years old – 50–100 mg PO twice daily Linear IgA bullous 50–100 mg PO twice daily > 8 years old – 50–100 mg PO twice dermatosis daily Mycobacterium 100 mg PO twice daily for 4–6 weeks > 8 years old – 50–100 mg PO twice marinum infection after clinical resolution daily for 4–6 weeks after clincial resolution Nocardiosis 100-200 mg PO daily for 2–4 weeks > 8 years old – 100-200 mg PO daily M for 2–4 weeks Pemphigus foliaceus 50–100 mg PO twice daily > 8 years old – 50–100 mg PO twice daily Perioral dermatitis 50–100 mg PO twice daily for at > 8 years old – 50–100 mg PO twice least 30 days daily for at least 30 days Rosacea 50–100 mg PO twice daily for at > 8 years
Recommended publications
  • Epidemiology of Dandruff, Scalp Pruritus and Associated Symptoms

    Epidemiology of Dandruff, Scalp Pruritus and Associated Symptoms

    Letters to the Editor 1 Epidemiology of Dandruff, Scalp Pruritus and Associated Symptoms Laurent Misery1,2, Nora Rahhali3, Antoine Duhamel4 and Charles Taieb3 1Laboratory of Skin Neurobiology, University of Brest, 2Department of Dermatology, University Hospital of Brest, FR-29609 Brest, 3Department of Public Health, Pierre Fabre Laboratories, Boulogne, and 4Ducray Laboratories, Lavaur, France. E-mail: [email protected] Accepted November 8, 2011. Dandruff, or pityriasis capitis, is the most common Table I. Scalp symptoms among subjects who reported dandruff [AQ1] symptom of seborrhoeic dermatitis (1). Dandruff is and those who did not usually defined as excessive flaking of the scalp. People Symptom All subjects, % Dandruff, % No dandruff, % p-value reporting dandruff often have seborrhoeic dermatitis, but Itching 21.49 51.06 15.62 < 0.0001 can also have other diseases, such as psoriasis or eczema. Prickling 14.91 31.91 11.51 < 0.0001 Although it is considered a very common condition, no Tightness 4.46 8.51 3.56 < 0.001 Pain 3.88 6.74 3.31 < 0.01 published epidemiological study evaluating the frequency Burning 2.35 4.26 1.97 0.02 of dandruff could be found in the literature. Scalp pruritus is also frequent and is often associated with dandruff. The aim of this study was to evaluate the prevalence of and severe in 11.3%, without any significant difference dandruff, scalp pruritus, and other associated symptoms, between these patients and those with pruritus without in the French population. dandruff. Patients with dandruff presented significantly more symptoms than those without dandruff: 49.3% (vs.
  • Meeting Program SID 2019 ANNUAL MEETING

    Meeting Program SID 2019 ANNUAL MEETING

    Meeting Program SID 2019 ANNUAL MEETING 2019 Annual Meeting Scientific 2019 Annual Meeting Program Chairs, Committee Committee on Education Members, and Reviewers Chairs and Committee CHAIRS Members Dan Kaplan, MD/PhD, University of Pittsburgh CHAIRS Ethan Lerner, MD/PhD, Mass General Hospital Heidi Kong, MD, National Insitutes of Health Todd Ridky, MD/PhD, University of Pennsylvania COMMITTEE MEMBERS Lloyd Miller, MD/PhD, Johns Hopkins University COMMITTEE MEMBERS Kevin Wang, MD/PhD, Stanford University My Mahoney, PhD, Thomas Jefferson University Spiro Getsios, PhD, Aspect Biosystems Alexander Marneros, MD/PhD, Harvard University Peggy Myung, MD/PhD, Yale University Robert Dellavalle, MD/PhD, University of Colorado Marjana Tomic-Canic PhD, University of Miami Amanda MacLeod, MD, Duke University Vladimir Botchkarev, MD/PhD, Boston University Cristina de Guzman Strong, PhD, Washington University-St. Louis Tissa Hata, MD, University of California, San Diego Maryam Asgari, MD, Massachusetts General Hospital Ken Tsai, MD/PhD, Moffitt Cancer Center and Paul Nghiem, MD/PhD, University of Washington Research Institute Richard Granstein, MD, Weill Cornell Medical School Sarah Millar, PhD, Mt. Sinai Medical School Matthew Vesley, MD/PhD, Yale University REVIEWERS Anna Di Nardo, MD/PhD Jennifer Gill, MD/PhD, University of Texas Southwestern Carolyn Lee, MD/PhD Jonathan Silverberg, MD/PhD ACKNOWLEDGEMENTS Bogi Andersen, MD The organizers of the 2019 SID Annual Meeting gratefully Kavita Sarin, MD/PhD acknowledge the sponsors, exhibitors, and participants whose Peter Koch, PhD Tiffany C. Scharschmidt, MD attendance has helped to make this meeting possible. Joseph Merola, MD Sakeen Kashem, MD/PhD Thomas Hultsch, MD Amanda MacLeod, MD Liang Deng, MD/PhD Ya-Chieh Hsu, PhD Crystal Aguh, MD Katherine Radek, PhD Paul Nghiem, MD/PhD Alicia Mathers, PhD Raymond Cho, MD Zelma Chiesa, MD Anna Mandinova, MD/PhD Brian Capell, MD/PhD Ryan R.
  • Racial and Gender Differences in the Presentation of Pruritus at John Hopkins Health System and Compared the Results to Those Seen Nationally

    Racial and Gender Differences in the Presentation of Pruritus at John Hopkins Health System and Compared the Results to Those Seen Nationally

    medicines Article Racial and Gender Differences in the Presentation of Pruritus Katherine A. Whang 1, Raveena Khanna 1 , Jamael Thomas 1,2 , Crystal Aguh 1 and Shawn G. Kwatra 1,3,* 1 Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; [email protected] (K.A.W.); [email protected] (R.K.); [email protected] (J.T.); [email protected] (C.A.) 2 School of Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA 3 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231, USA * Correspondence: [email protected]; Tel.: +1-410-955-8662 Received: 27 June 2019; Accepted: 25 September 2019; Published: 27 September 2019 Abstract: Background: Pruritus is a common disease symptom with a variety of etiologies known to reduce patient quality of life. We aimed to characterize the racial and gender differences in the presentation of pruritus for itch-related patient visits both within a single institution and nationally. Methods: Cross sectional study of patients 18 years old seen at Johns Hopkins Health System ≥ between 1/1/12 and 1/1/18. Results were compared to data from 2005–2011 from the National Ambulatory Medical Care Survey (NAMCS) and the National Health Ambulatory Medical Care Survey (NHAMCS). Results: Our findings indicate that itch patients at JHHS (n = 18,753) were more likely to be black compared to white patients (37% vs. 19%, p < 0.01) when compared to patients without itch—a trend also noted nationally based on data from NAMCS/NHAMCS (26% vs. 21%, p = 0.05). Black itch patients are also more likely to be diagnosed with prurigo nodularis (OR 2.37, p < 0.0001), lichen planus (OR 1.22, p < 0.0001), and atopic dermatitis OR 1.51, p < 0.0001).

  • Copyrighted Material

    1 Index Note: Page numbers in italics refer to figures, those in bold refer to tables and boxes. References are to pages within chapters, thus 58.10 is page 10 of Chapter 58. A definition 87.2 congenital ichthyoses 65.38–9 differential diagnosis 90.62 A fibres 85.1, 85.2 dermatomyositis association 88.21 discoid lupus erythematosus occupational 90.56–9 α-adrenoceptor agonists 106.8 differential diagnosis 87.5 treatment 89.41 chemical origin 130.10–12 abacavir disease course 87.5 hand eczema treatment 39.18 clinical features 90.58 drug eruptions 31.18 drug-induced 87.4 hidradenitis suppurativa management definition 90.56 HLA allele association 12.5 endocrine disorder skin signs 149.10, 92.10 differential diagnosis 90.57 hypersensitivity 119.6 149.11 keratitis–ichthyosis–deafness syndrome epidemiology 90.58 pharmacological hypersensitivity 31.10– epidemiology 87.3 treatment 65.32 investigations 90.58–9 11 familial 87.4 keratoacanthoma treatment 142.36 management 90.59 ABCA12 gene mutations 65.7 familial partial lipodystrophy neutral lipid storage disease with papular elastorrhexis differential ABCC6 gene mutations 72.27, 72.30 association 74.2 ichthyosis treatment 65.33 diagnosis 96.30 ABCC11 gene mutations 94.16 generalized 87.4 pityriasis rubra pilaris treatment 36.5, penile 111.19 abdominal wall, lymphoedema 105.20–1 genital 111.27 36.6 photodynamic therapy 22.7 ABHD5 gene mutations 65.32 HIV infection 31.12 psoriasis pomade 90.17 abrasions, sports injuries 123.16 investigations 87.5 generalized pustular 35.37 prepubertal 90.59–64 Abrikossoff
  • Environmental Health Criteria 242

    Environmental Health Criteria 242

    INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY Environmental Health Criteria 242 DERMAL EXPOSURE IOMC INTER-ORGANIZATION PROGRAMME FOR THE SOUND MANAGEMENT OF CHEMICALS A cooperative agreement among FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization The International Programme on Chemical Safety (IPCS) was established in 1980. The overall objec- tives of the IPCS are to establish the scientific basis for assessment of the risk to human health and the environment from exposure to chemicals, through international peer review processes, as a prerequi- site for the promotion of chemical safety, and to provide technical assistance in strengthening national capacities for the sound management of chemicals. This publication was developed in the IOMC context. The contents do not necessarily reflect the views or stated policies of individual IOMC Participating Organizations. The Inter-Organization Programme for the Sound Management of Chemicals (IOMC) was established in 1995 following recommendations made by the 1992 UN Conference on Environment and Development to strengthen cooperation and increase international coordination in the field of chemical safety. The Participating Organizations are: FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD. The purpose of the IOMC is to promote coordination of the policies and activities pursued by the Participating Organizations, jointly or separately, to achieve the sound management of chemicals in relation to human health and the environment. WHO Library Cataloguing-in-Publication Data Dermal exposure. (Environmental health criteria ; 242) 1.Hazardous Substances - poisoning.
  • 12.2% 116000 125M Top 1% 154 4300

    12.2% 116000 125M Top 1% 154 4300

    We are IntechOpen, the world’s leading publisher of Open Access books Built by scientists, for scientists 4,300 116,000 125M Open access books available International authors and editors Downloads Our authors are among the 154 TOP 1% 12.2% Countries delivered to most cited scientists Contributors from top 500 universities Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI) Interested in publishing with us? Contact [email protected] Numbers displayed above are based on latest data collected. For more information visit www.intechopen.com ProvisionalChapter chapter 4 Occupational Acne Occupational Acne Betul Demir and Demet Cicek Betul Demir and Demet Cicek Additional information is available at the end of the chapter Additional information is available at the end of the chapter http://dx.doi.org/10.5772/64905 Abstract Occupational and environmental acne is a dermatological disorder associated with industrial exposure. Polyhalogenated hydrocarbons, coal tar and products, petrol, and other physical, chemical, and environmental agents are suggested to play a role in the etiology of occupational acne. The people working in the field of machine, chemistry, and electrical industry are at high risk. The various occupational acne includes chloracne, coal tar, and oil acne. The most common type in clinic is the comedones, and it is also seen as papule, pustule, and cystic lesions. Histopathological examination shows epidermal hyperplasia, while follicular and sebaceous glands are replaced by keratinized epidermal cells. Topical or oral retinoic acids and oral antibiotics could be used in treatment. The improvement in working conditions, taking preventive measures, and education of the workers could eliminate occupational acne as a problem.
  • Tissue Liver X-Receptor Alpha (Lxrα) Level in Acne Vulgaris

    Tissue Liver X-Receptor Alpha (Lxrα) Level in Acne Vulgaris

    TISSUE LIVER X-RECEPTOR ALPHA (LXRα) LEVEL IN ACNE VULGARIS Thesis Submitted for the fulfillment of Master Degree in Dermatology and Venereology BY Eman Abdelhamed Aly Nada (M.B.B.Ch) Supervisors Dr. Shereen Osama Tawfic Assistant prof.of Dermatology Faculty of Medicine Cairo University Dr. Marwa Ahmed Ezzat Lecturer of Dermatology Faculty of Medicine Cairo University Dr. Olfat Gamil Shaker Professor of Medical Biochemistry Faculty of Medicine Cairo University Faculty of Medicine Cairo University 2012 1 Acknowledgment First and foremost, I am thankful to God, for without his help I could not finish this work. I would like to express my sincere gratitude and appreciation to Dr. Shereen Osama Tawfic, Assistant Professor of Dermatology, Faculty of Medicine, Cairo University, for giving me the honor for working under her supervision and for her great support and stimulating views. Special thanks and deepest gratitude to Dr. Marwa Ahmed Ezzat, Lecturer of Dermatology, Faculty of Medicine, Cairo University, for her advice, support and encouragement all the time for a better performance. I am deeply thankful to Prof. Dr. Olfat Gamil Shaker, Professor of Medical Biochemistry, Faculty of Medicine, Cairo University for her sincere scientific and moral help in accomplishing the practical part of this study. I would like to extend my warmest gratitude to Prof. Dr. Manal Abdelwahed Bosseila, Professor of Dermatology, Faculty of Medicine, Cairo University, whose hard and faithful efforts have helped me to do this work. Furthermore, I would like to thank my family who stood behind me to finish this work and for their great support to me.
  • Management of Acne

    Management of Acne

    Review CMAJ Management of acne John Kraft MD, Anatoli Freiman MD cne vulgaris has a substantial impact on a patient’s Key points quality of life, affecting both self-esteem and psychoso- cial development.1 Patients and physicians are faced • Effective therapies for acne target one or more pathways A in the pathogenesis of acne, and combination therapy with many over-the-counter and prescription acne treatments, gives better results than monotherapy. and choosing the most effective therapy can be confusing. • Topical therapies are the standard of care for mild to In this article, we outline a practical approach to managing moderate acne. acne. We focus on the assessment of acne, use of topical • Systemic therapies are usually reserved for moderate or treatments and the role of systemic therapy in treating acne. severe acne, with a response to oral antibiotics taking up Acne is an inflammatory disorder of pilosebaceous units to six weeks. and is prevalent in adolescence. The characteristic lesions are • Hormonal therapies provide effective second-line open (black) and closed (white) comedones, inflammatory treatment in women with acne, regardless of the presence papules, pustules, nodules and cysts, which may lead to scar- or absence of androgen excess. ring and pigmentary changes (Figures 1 to 4). The pathogene- sis of acne is multifactorial and includes abnormal follicular keratinization, increased production of sebum secondary to ing and follicle-stimulating hormone levels.5 Pelvic ultra- hyperandrogenism, proliferation of Propionibacterium acnes sonography may show the presence of polycystic ovaries.5 In and inflammation.2,3 prepubertal children with acne, signs of hyperandrogenism Lesions occur primarily on the face, neck, upper back and include early-onset accelerated growth, pubic or axillary hair, chest.4 When assessing the severity of the acne, one needs to body odour, genital maturation and advanced bone age.
  • Three Steps to Overcoming Scalp Itch an Emphasis on Accurate Diagnosis and Patient-Friendly Interventions Leads to Successful Management of This Common Complaint

    Three Steps to Overcoming Scalp Itch an Emphasis on Accurate Diagnosis and Patient-Friendly Interventions Leads to Successful Management of This Common Complaint

    Winter 2007 Vol. 3, No. 1 Editor’s Letter & Contributors. 3 More on Negotiations . 4 Professional Resolutions for 2007 . 4 Sun Protection Education. 7 Three Steps to Overcoming Scalp Itch An emphasis on accurate diagnosis and patient-friendly interventions leads to successful management of this common complaint. By Coyle S. Connolly, DO, and Gerard W. Stroup, PA-C hen a patient presents to the dermatology office complaining of scalp itch, he or she Wmay report frustration with the recurrent symptom, a history of failed at-home therapies, and concern about the appearance of associated lesions on the scalp. The clinician recognizes that several der- matoses may be associated with scalp itch in children and adults (Tables 1, 2). Successful management depends on accurate diagnosis and initiation of an effective, patient-friendly treatment regimen. Step 1.Visual Examination Evaluation of primary lesions will provide clues to the proper diagnosis. While thickened, silver, scaling plaques obviously indicate psoriasis, a diffuse, fine, white scale—with or without erythema—is a sign of seborrheic dermatitis. Scaling in tinea capitis tends to be well-demarcated and erythematous, with cen- tral clearing and fine peripheral scale, with or with- out associated hair loss. In African-American patients tinea capitis can resemble non-inflammato- ® 6 e Salary and Benefits: Negotiate from Strength c tions.” This is far below the American Academy of Physician i nyone seeking employment knows that the ideal posi- t tion may be elusive. Sometimes a candidate must set Assistants’ (AAPA) recently reported average national salary for c Aaside certain less important preferences in order to find full-time clinically practicing PAs of $84,396 (aapa.org).
  • 7Th World Congress for Hair Research

    7Th World Congress for Hair Research

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector ABSTRACTS 7th World Congress for Hair Research ALOPECIA AREATA P001 P002 Hair follicle cycle and inflammatory infiltrate in alopecia areata at early stage Exomic sequencing of immune-related genes reveals novel candidate variants XT Zhang, Y Zhao, B Zhang, MZ Cai, YG Gong, T Ye and XQ Zhang The First Affiliated Hospital of associated with alopecia universalis Sun Yat-Sen University of Medical Sciences, Guangzhou, China HH Ryu1,SLee2,3, SH Paik1,SJJo1,J-SSeo2,3,4,J-IKim2,3,4 and OS Kwon1,5,6 1Department of Objective: To investigate the histopathological features including changing of hair follicle cycle and the Dermatology, Seoul National University College of Medicine, Seoul, Republic of Korea; 2Department inflammatory infiltrate of lymphocytes, eosinophils, and mast cells in alopecia areata (AA). of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea; Method: Clinical, laboratory, and pathological features of 136 patients with AA were 3Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Republic investigated. of Korea; 4Department of Biochemistry and Molecular Biology, Seoul National University College of Results: Follicular counts from biopsy specimens of the 136 patients showed largely decreased Medicine, Seoul, Republic of Korea; 5Laboratory of Cutaneous Aging and Hair Research, Clinical anagen/telogen and terminal-vellus ratios. ‘‘Swarm-of-bees’’ peribulbar lymphoid infiltration existed Research Institute, Seoul National University Hospital, Seoul, Republic of Korea and 6Institute of in 73.52% (100/136) of the patients, and those with it either had a shorter duration or had active hair Dermatological Science, Seoul National University College of Medicine, Seoul, Republic of Korea loss.
  • The Clinical Conundrum of Pruritus Victoria Garcia-Albea, Karen Limaye

    The Clinical Conundrum of Pruritus Victoria Garcia-Albea, Karen Limaye

    FEATURE ARTICLE The Clinical Conundrum of Pruritus Victoria Garcia-Albea, Karen Limaye ABSTRACT: Pruritus is a common complaint for derma- Pruritus is also the most common symptom in derma- tology patients. Diagnosing the cause of pruritus can tological disease and can be a symptom of several sys- be difficult and is often frustrating for patients and pro- temic diseases (Bernhard, 1994). The overall incidence viders. Even after the diagnosis is made, it can be a chal- of pruritus is unknown because there are no epidemio- lenge to manage and relieve pruritus. This article reviews logical databases for pruritus (Norman, 2003). According common and uncommon causes of pruritus and makes to a 2003 study, pruritus and xerosis are the most com- recommendations for proper and thorough evaluation mon dermatological problems encountered in nursing and management. home patients (Norman, 2003). Key words: Itch, Pruritus INTRODUCTION ETIOLOGY Pruritus (itch) is the most frequent symptom in derma- The skin is equipped with a network of afferent sensory tology (Serling, Leslie, & Maurer, 2011). Itch is the pre- and efferent autonomic nerve branches that respond to dominant symptom associated with acute and chronic various chemical mediators found in the skin (Bernhard, cutaneous disease and is a major symptom in systemic dis- 1994). It is believed that maximal itch production is ease (Elmariah & Lerner, 2011; Steinhoff, Cevikbas, Ikoma, achieved at the basal layer of the epidermis, below which & Berger, 2011). It can be a frustration for both the patient pain is perceived (Bernhard, 1994). Autonomic nerves in- and the clinician. This article will attempt to provide an nervate hair follicles, pili erector muscles, blood vessels, overview of pruritus, a method for thorough and com- eccrine, apocrine, and sebaceous glands (Bernhard, 1994).
  • Pathogenesis and Treatment of Chronic Pruritus

    Pathogenesis and Treatment of Chronic Pruritus

    Pathogenesis and of Chronic Treatment Pruritus • Shawn G. Kwatra Pathogenesis and Treatment of Chronic Pruritus Edited by Shawn G. Kwatra Printed Edition of the Special Issue Published in Medicines www.mdpi.com/journal/medicines Pathogenesis and Treatment of Chronic Pruritus Pathogenesis and Treatment of Chronic Pruritus Editor Shawn G. Kwatra MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade • Manchester • Tokyo • Cluj • Tianjin Editor Shawn G. Kwatra Johns Hopkins University School of Medicine USA Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Medicines (ISSN 2305-6320) (available at: https://www.mdpi.com/journal/medicines/special issues/pathogenesis chronic pruritus). For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03943-100-7 (Hbk) ISBN 978-3-03943-101-4 (PDF) c 2020 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND. Contents About the Editor .............................................. vii Kyle A. Williams and Shawn G. Kwatra Emerging Research in Chronic Pruritus: From Bedside to Bench and Back Again Reprinted from: Medicines 2020, 7, 24, doi:10.3390/medicines7050024 ...............